bimagrumab vs REGN20934
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Activin/myostatin type II receptor · full Obesity pipeline
bimagrumab
Developed by Eli Lilly and partners
NCT05616013 · Phase 2 · completed
This randomized, double-blind, placebo-controlled trial enrolled 507 adults and used a hard clinical primary endpoint, change in body weight at Week 48. The primary endpoint comparison showed a statistically significant advantage for most active treatment combinations over placebo, including the highest-dose combination (bimagrumab 30 mg/kg + semaglutide 2.4 mg), but the 10 mg/kg bimagrumab monotherapy arm missed significance, yielding a mixed primary endpoint result. Because the primary endpoint was not uniformly met across the multiple prespecified comparisons, the overall evidence is moderate despite the strong design.
Reported efficacy
Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): 30 mg/kg Bimagrumab -9.25 kilogram (kg) (Standard Error 1.33) | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide -12.73 kilogram (kg) (Standard Error 1.29) | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide -14.31 kilogram (kg) (Standard Error 1.34) | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide -13.86 kilogram (kg) (Standard Error 1.29) | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide -17.79 kilogram (kg) (Standard Error 1.29) vs Placebo + 1.0 mg Semaglutide -9.76 kilogram (kg) (Standard Error 1.25) | Placebo + 2.4 mg Semaglutide -14.24 kilogram (kg) (Standard Error 1.17) (mixed)
Result source: NCT05616013
REGN20934
Developed by Regeneron Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT07594093 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | bimagrumab | REGN20934 |
|---|---|---|
| Body weight, % change | —Not reported | —Not reported |
| Weight loss of 5% or more | —Not reported | —Not reported |
| Weight loss of 10% or more | —Not reported | —Not reported |
| Waist circumference, change (cm) | -9 vs 0.5−9.4 vs placeboNCT0300528811 other results
| —Not reported |
Body weight, % change
- bimagrumab
- —Not reported
- REGN20934
- —Not reported
Weight loss of 5% or more
- bimagrumab
- —Not reported
- REGN20934
- —Not reported
Weight loss of 10% or more
- bimagrumab
- —Not reported
- REGN20934
- —Not reported
Waist circumference, change (cm)
- bimagrumab
- -9 vs 0.5−9.4 vs placeboNCT03005288
11 other results
- -5.0 vs -0.9 NCT03005288
- -13.0 vs -14.7 NCT05616013
- -18.2 vs -14.7 NCT05616013
- -21.3 vs -14.7 NCT05616013
- -10.6 vs -13.6 NCT05616013
- -15.8 vs -13.6 NCT05616013
- -19.0 vs -13.6 NCT05616013
- -15.6 vs -14.7 NCT05616013
- -18.1 vs -14.7 NCT05616013
- -14.6 vs -13.6 NCT05616013
- -16.6 vs -13.6 NCT05616013
- REGN20934
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
REGN20934: no structured comparison results are available for Obesity.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. bimagrumab: 4 of 4 rows · REGN20934: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | bimagrumab |
|---|---|
| Dropout rate | 52.6%30 mg/kga NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2 show 9 more results33.9%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · combination · Obesity · phase 2 38.6%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · combination · Obesity · phase 2 50%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · combination · Obesity · phase 2 37.5%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · combination · Obesity · phase 2 30.8%10 mg/kg NCT03005288 · Phase 2 · registry result, not featured evidence 65.5%30mg/kg NCT01433263 · Phase 2 · registry result, not featured evidence —30mg/kg NCT01433263 · Phase 2 · registry result, not featured evidence —30mg/kg NCT01433263 · Phase 2 · registry result, not featured evidence —30mg/kg NCT01433263 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 15.8%30 mg/kga NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2 show 9 more results10.7%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · combination · Obesity · phase 2 1.8%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · combination · Obesity · phase 2 14.3%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · combination · Obesity · phase 2 5.4%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · combination · Obesity · phase 2 12.8%10 mg/kg NCT03005288 · Phase 2 · registry result, not featured evidence 10.3%30mg/kg NCT01433263 · Phase 2 · registry result, not featured evidence —30mg/kg NCT01433263 · Phase 2 · registry result, not featured evidence —30mg/kg NCT01433263 · Phase 2 · registry result, not featured evidence —30mg/kg NCT01433263 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 14%30 mg/kga NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2 show 9 more results10.7%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · combination · Obesity · phase 2 12.7%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · combination · Obesity · phase 2 12.5%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · combination · Obesity · phase 2 14.5%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · combination · Obesity · phase 2 8.1%10 mg/kg NCT03005288 · Phase 2 · registry result, not featured evidence —30mg/kg NCT01433263 · Phase 2 · registry result, not featured evidence 62.1%30mg/kg NCT01433263 · Phase 2 · registry result, not featured evidence 36.8%30mg/kg NCT01433263 · Phase 2 · registry result, not featured evidence 33.3%30mg/kg NCT01433263 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 30 mg/kga muscle spasms 71.9% diarrhoea 50.9% acne 49.1% NCT05616013 · Phase 2 · monotherapy · Obesity · phase 2 show 8 more results30 mg/kg + 1.0 mg muscle spasms 64.3% acne 55.4% diarrhoea 44.6% NCT05616013 · Phase 2 · combination · Obesity · phase 2 30 mg/kg + 2.4 mg muscle spasms 63.6% acne 52.7% diarrhoea 49.1% NCT05616013 · Phase 2 · combination · Obesity · phase 2 10 mg/kg + 1.0 mg muscle spasms 57.1% diarrhoea 48.2% acne 42.9% NCT05616013 · Phase 2 · combination · Obesity · phase 2 10 mg/kg + 2.4 mg muscle spasms 65.5% nausea 61.8% diarrhoea 52.7% NCT05616013 · Phase 2 · combination · Obesity · phase 2 10 mg/kg diarrhoea 40.5% (placebo 10.5%) muscle spasms 40.5% (placebo 2.6%) upper respiratory tract infection 16.2% (placebo 13.2%) NCT03005288 · Phase 2 · registry result, not featured evidence 30mg/kg fatigue 20.7% (placebo 10.7%) diarrhoea 17.2% (placebo 10.7%) nausea 17.2% (placebo 3.6%) NCT01433263 · Phase 2 · registry result, not featured evidence 30mg/kg fatigue 21.1% (placebo 10.7%) anaemia 10.5% (placebo 21.4%) neutropenia 10.5% (placebo 10.7%) NCT01433263 · Phase 2 · registry result, not featured evidence 30mg/kg diarrhoea 23.8% (placebo 10.7%) anaemia 14.3% (placebo 21.4%) amylase increased 9.5% (placebo 0%) NCT01433263 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 5 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
bimagrumab
show 6 more results
show 11 more results
show 21 more results
show 19 more results
show 4 more results
show 21 more results
show 19 more results
show 9 more results
show 6 more results
show 14 more results
show 14 more results
show 1 more result
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bimagrumab's landscape · REGN20934's landscape